Eloísa Riva

1.5k total citations
39 papers, 161 citations indexed

About

Eloísa Riva is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Eloísa Riva has authored 39 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 13 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Eloísa Riva's work include Multiple Myeloma Research and Treatments (18 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Peptidase Inhibition and Analysis (9 papers). Eloísa Riva is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Peptidase Inhibition and Analysis (9 papers). Eloísa Riva collaborates with scholars based in Uruguay, Brazil and Argentina. Eloísa Riva's co-authors include Pablo Cabral, Marcelo Fernández, Roger Chammas, T. Caraceni, G. Calderini, P. L. Morselli, A. Consolazione, Roberto Spreafico, F. Girotti and S. Algeri and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Eloísa Riva

34 papers receiving 154 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eloísa Riva Uruguay 7 64 47 38 38 29 39 161
Scott H. Bradshaw Canada 8 52 0.8× 46 1.0× 30 0.8× 11 0.3× 14 0.5× 20 177
Jacinth Joseph United States 6 52 0.8× 64 1.4× 65 1.7× 7 0.2× 12 0.4× 16 179
Emad Ibrahim United States 7 49 0.8× 18 0.4× 65 1.7× 15 0.4× 7 0.2× 8 147
Manmohan R. Leleti United States 7 71 1.1× 15 0.3× 42 1.1× 10 0.3× 14 0.5× 31 262
Cristina Calderón‐Cabrera Spain 8 24 0.4× 38 0.8× 31 0.8× 13 0.3× 7 0.2× 16 127
Kelley R. Jordan United States 10 34 0.5× 64 1.4× 20 0.5× 3 0.1× 24 0.8× 14 232
Oscar Lahoud United States 8 99 1.5× 89 1.9× 70 1.8× 9 0.2× 11 0.4× 44 197
Shun Ke China 9 307 4.8× 14 0.3× 23 0.6× 16 0.4× 9 0.3× 11 385
Jack Godsell Australia 6 40 0.6× 23 0.5× 26 0.7× 18 0.5× 4 0.1× 9 231
Bernard S. Buetow United States 8 76 1.2× 13 0.3× 114 3.0× 23 0.6× 3 0.1× 13 228

Countries citing papers authored by Eloísa Riva

Since Specialization
Citations

This map shows the geographic impact of Eloísa Riva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eloísa Riva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eloísa Riva more than expected).

Fields of papers citing papers by Eloísa Riva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eloísa Riva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eloísa Riva. The network helps show where Eloísa Riva may publish in the future.

Co-authorship network of co-authors of Eloísa Riva

This figure shows the co-authorship network connecting the top 25 collaborators of Eloísa Riva. A scholar is included among the top collaborators of Eloísa Riva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eloísa Riva. Eloísa Riva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Riva, Eloísa, et al.. (2023). Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay. Hematology Transfusion and Cell Therapy. 46(4). 434–442. 2 indexed citations
2.
Machado, Camila Maria Longo, Camila de Godoi Carneiro, Mara de Souza Junqueira, et al.. (2023). 99mTc-HYNIC/Cy7-Fab(Bevacizumab): su empleo como agente de imagen en mieloma múltiple. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 42(1). e302–e302.
3.
Martínez‐Cordero, Humberto, et al.. (2023). Renal Failure in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Stem Cell Transplant in LATAM - on Behalf of Gelamm. Blood. 142(Supplement 1). 3346–3346. 1 indexed citations
4.
5.
Slavutsky, Irma, et al.. (2022). Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting. Current Problems in Cancer. 47(1). 100916–100916. 4 indexed citations
6.
Riva, Eloísa, et al.. (2022). Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis. Journal of Oncology Pharmacy Practice. 28(7). 1659–1663.
7.
Machado, Camila Maria Longo, Camila de Godoi Carneiro, Mara de Souza Junqueira, et al.. (2021). 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents. Anti-Cancer Agents in Medicinal Chemistry. 21(14). 1883–1893. 5 indexed citations
8.
Riva, Eloísa, et al.. (2021). Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population. Medicine and Pharmacy Reports. 94(1). 48–52. 1 indexed citations
9.
Guillermo, Cecilia, et al.. (2021). Spinal cord compression due to a solitary, bulky plasmacytoma of posterior mediastinum.. SHILAP Revista de lepidopterología. 16(7). 1622–1627. 1 indexed citations
10.
Riva, Eloísa, et al.. (2020). Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology Transfusion and Cell Therapy. 43(3). 295–302. 7 indexed citations
11.
12.
13.
14.
Riva, Eloísa, Camila Peña, Guillermo J. Ruíz‐Argüelles, et al.. (2018). Significant Differences in Test Availability and Access to Novel Drugs for Multiple Myeloma between Public and Private Hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM). Blood. 132(Supplement 1). 2244–2244. 3 indexed citations
15.
García, María Fernanda, Marcelo Fernández, Hugo Cerecetto, et al.. (2017). 99mTc-HYNIC-Fab(Bevacizumab): potencial agente de imagen para diagnóstico de Linfoma No Hodgkin. 36(2). 1 indexed citations
16.
Machado, Camila Maria Longo, María Fernanda García, Juan Pablo Gambini, et al.. (2017). Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. Oncology. 92(4). 229–242. 14 indexed citations
17.
Sung, Lillian, Eduardo Magalhães Rego, Eloísa Riva, et al.. (2016). Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. Journal of Cancer Education. 32(4). 845–849. 4 indexed citations
18.
Riva, Eloísa, et al.. (2015). Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses. Leukemia & lymphoma. 57(6). 1363–1366. 2 indexed citations
19.
20.
Castellano, G., Marcelo Fernández, Eloísa Riva, et al.. (2011). [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies. Applied Radiation and Isotopes. 69(7). 924–928. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott H. Bradshaw Breakdown of academic impact, for papers by Jacinth Joseph Breakdown of academic impact, for papers by Emad Ibrahim Breakdown of academic impact, for papers by Manmohan R. Leleti Breakdown of academic impact, for papers by Cristina Calderón‐Cabrera Breakdown of academic impact, for papers by Kelley R. Jordan Breakdown of academic impact, for papers by Oscar Lahoud Breakdown of academic impact, for papers by Shun Ke Breakdown of academic impact, for papers by Jack Godsell Breakdown of academic impact, for papers by Bernard S. Buetow
Rankless by CCL
2026